Trump Signs Executive Order on Psychedelic Therapy Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CMPS?
Source: Fool
- Accelerated Review Process: President Trump's executive order aims to shorten the timeline for clinical trials and regulatory reviews of psychedelic therapies, which will enhance acceptance among patients and providers, thereby increasing the investment value of the psychedelics sector.
- COMP360 Clinical Progress: Compass Pathways' COMP360 is in pivotal phase 3 development, demonstrating significant efficacy in treating treatment-resistant depression, with plans to submit a New Drug Application in Q4 2023, marking a critical milestone in its clinical advancement.
- Sufficient Funding Assurance: Compass Pathways reported $149.6 million in cash and cash equivalents at the end of 2025, with an annual cash burn of $120 million to $145 million, ensuring it can smoothly advance to the final development stage without the risk of running out of capital.
- Institutional Investor Confidence: Approximately 46% of Compass Pathways' shares are held by institutional investors and hedge funds, reflecting strong market confidence in its clinical data and regulatory progress, further enhancing its competitiveness in the psychedelics field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.750
Low
8.00
Averages
18.43
High
40.00
Current: 8.750
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump's Executive Order Accelerates Psychedelic Drug Approvals
- Regulatory Acceleration: Trump's executive order aims to expedite clinical trials and regulatory reviews for psychedelic therapies, potentially allowing companies like Compass Pathways to secure approvals faster, thereby boosting investor confidence in psychedelic stocks.
- Strong Cash Position: Compass Pathways currently holds approximately $150 million in cash, which is expected to fund its NDA submission by 2025 without the risk of near-term dilution, ensuring its survival in the competitive biotech landscape.
- Significant Clinical Progress: Compass's COMP360 therapy has shown positive late-stage data in phase 3 trials, demonstrating clinically meaningful effects and a well-tolerated profile, laying a solid foundation for its upcoming FDA submission.
- Institutional Investor Confidence: With about 46% of Compass Pathways' shares owned by institutional investors and hedge funds, this reflects strong market confidence in its clinical data and regulatory timeline, enhancing the company's competitive edge in the psychedelics sector.
See More
Trump Signs Executive Order on Psychedelic Therapy Review
- Accelerated Review Process: President Trump's executive order aims to shorten the timeline for clinical trials and regulatory reviews of psychedelic therapies, which will enhance acceptance among patients and providers, thereby increasing the investment value of the psychedelics sector.
- COMP360 Clinical Progress: Compass Pathways' COMP360 is in pivotal phase 3 development, demonstrating significant efficacy in treating treatment-resistant depression, with plans to submit a New Drug Application in Q4 2023, marking a critical milestone in its clinical advancement.
- Sufficient Funding Assurance: Compass Pathways reported $149.6 million in cash and cash equivalents at the end of 2025, with an annual cash burn of $120 million to $145 million, ensuring it can smoothly advance to the final development stage without the risk of running out of capital.
- Institutional Investor Confidence: Approximately 46% of Compass Pathways' shares are held by institutional investors and hedge funds, reflecting strong market confidence in its clinical data and regulatory progress, further enhancing its competitiveness in the psychedelics field.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Compass Pathways Collaborates with Osmind to Advance Psychedelic Treatment Delivery
- Collaboration Context: The partnership between Compass Pathways and Osmind aims to educate small-to-medium-sized clinics on effectively delivering FDA-approved psychedelic treatments, with Osmind collaborating with over 1,000 clinics in the U.S., indicating a growing market demand.
- Stock Reaction: Following the collaboration announcement, Compass Pathways' stock rose 5% in premarket trading after a 42% surge the previous day, marking its best single-day performance since 2026, reflecting strong investor optimism regarding the partnership.
- Treatment Approach: This collaboration will assist Osmind in understanding how to administer the COMP360 treatment, which currently holds FDA's “Breakthrough Therapy” designation for treatment-resistant depression, showcasing the company's innovative potential in the mental health sector.
- Market Outlook: With President Trump’s executive order to expedite FDA reviews for psychedelic treatments and increase federal research funding, Compass Pathways' collaboration not only enhances its market position but may also lay the groundwork for future treatment models, driving overall industry growth.
See More
Apple CEO Transition Sparks Market Reactions
- Apple CEO Change: Apple announced that hardware chief John Ternus will replace Tim Cook as CEO in September, with Cook transitioning to executive chairman; this surprising move shocked investors but is seen positively, as Ternus must address Apple's lag in artificial intelligence, impacting the company's strategic direction.
- Fed Nomination Hearing: Trump's nominee for Federal Reserve chair, Kevin Warsh, will face the Senate Banking Committee for confirmation, emphasizing the need for Fed independence from political influence, a stance that may affect his confirmation prospects amid Trump's push for lower interest rates.
- Market Volatility: The Nasdaq Composite ended its longest winning streak since 1992, while the S&P 500 also retreated, as market uncertainty grew due to Trump's military threats against Iran; however, small-cap stocks showed resilience, with the Russell 2000 reaching new highs.
- UnitedHealth Group Strong Performance: UnitedHealth Group's first-quarter results exceeded expectations, leading to a more than 7% stock price increase, driven by improved management of medical costs and a favorable medical benefit ratio, with optimistic earnings outlook for 2026 further boosting investor confidence.
See More
Apple's CEO Transition Sparks Market Reactions
- CEO Transition Impact: Apple announced that hardware chief John Ternus will replace Tim Cook as CEO in September, with Cook moving to executive chairman; this shocking news is viewed positively as Ternus faces the challenge of bridging the AI gap with competitors.
- Fed Nomination Hearing: Kevin Warsh, Trump's nominee for Federal Reserve chair, will face the Senate Banking Committee for confirmation, emphasizing the need for Fed independence from political influence, a stance that may affect his confirmation process.
- Market Volatility: The Nasdaq Composite ended its longest winning streak since 1992, while the S&P 500 also retreated, as market uncertainty grew due to Trump's military threats against Iran, although small-cap stocks showed strong performance.
- UnitedHealth Group's Strong Performance: UnitedHealth Group's first-quarter results exceeded expectations, leading to a more than 7% stock price increase and an upgraded earnings outlook for 2026, driven by improved management of medical costs, which is crucial for its profitability.
See More
Trump's Executive Order Accelerates Psychedelic Drug Approvals
- Regulatory Acceleration: Trump's executive order aims to expedite clinical trials and regulatory reviews for psychedelic therapies, potentially allowing companies like Compass Pathways to secure approvals faster, thereby boosting investor confidence in psychedelic stocks.
- Strong Cash Position: Compass Pathways currently holds approximately $150 million in cash, which is expected to fund its NDA submission by 2025 without the risk of near-term dilution, ensuring its survival in the competitive biotech landscape.
- Significant Clinical Progress: Compass's COMP360 therapy has shown positive late-stage data in phase 3 trials, demonstrating clinically meaningful effects and a well-tolerated profile, laying a solid foundation for its upcoming FDA submission.
- Institutional Investor Confidence: With about 46% of Compass Pathways' shares owned by institutional investors and hedge funds, this reflects strong market confidence in its clinical data and regulatory timeline, enhancing the company's competitive edge in the psychedelics sector.
See More
Trump Signs Executive Order on Psychedelic Therapy Review
- Accelerated Review Process: President Trump's executive order aims to shorten the timeline for clinical trials and regulatory reviews of psychedelic therapies, which will enhance acceptance among patients and providers, thereby increasing the investment value of the psychedelics sector.
- COMP360 Clinical Progress: Compass Pathways' COMP360 is in pivotal phase 3 development, demonstrating significant efficacy in treating treatment-resistant depression, with plans to submit a New Drug Application in Q4 2023, marking a critical milestone in its clinical advancement.
- Sufficient Funding Assurance: Compass Pathways reported $149.6 million in cash and cash equivalents at the end of 2025, with an annual cash burn of $120 million to $145 million, ensuring it can smoothly advance to the final development stage without the risk of running out of capital.
- Institutional Investor Confidence: Approximately 46% of Compass Pathways' shares are held by institutional investors and hedge funds, reflecting strong market confidence in its clinical data and regulatory progress, further enhancing its competitiveness in the psychedelics field.
See More
Trump Signs Order to Accelerate Psychedelic Drug Research
- Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
- Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
- Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
- Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
See More
Compass Pathways Collaborates with Osmind to Advance Psychedelic Treatment Delivery
- Collaboration Context: The partnership between Compass Pathways and Osmind aims to educate small-to-medium-sized clinics on effectively delivering FDA-approved psychedelic treatments, with Osmind collaborating with over 1,000 clinics in the U.S., indicating a growing market demand.
- Stock Reaction: Following the collaboration announcement, Compass Pathways' stock rose 5% in premarket trading after a 42% surge the previous day, marking its best single-day performance since 2026, reflecting strong investor optimism regarding the partnership.
- Treatment Approach: This collaboration will assist Osmind in understanding how to administer the COMP360 treatment, which currently holds FDA's “Breakthrough Therapy” designation for treatment-resistant depression, showcasing the company's innovative potential in the mental health sector.
- Market Outlook: With President Trump’s executive order to expedite FDA reviews for psychedelic treatments and increase federal research funding, Compass Pathways' collaboration not only enhances its market position but may also lay the groundwork for future treatment models, driving overall industry growth.
See More
Apple CEO Transition Sparks Market Reactions
- Apple CEO Change: Apple announced that hardware chief John Ternus will replace Tim Cook as CEO in September, with Cook transitioning to executive chairman; this surprising move shocked investors but is seen positively, as Ternus must address Apple's lag in artificial intelligence, impacting the company's strategic direction.
- Fed Nomination Hearing: Trump's nominee for Federal Reserve chair, Kevin Warsh, will face the Senate Banking Committee for confirmation, emphasizing the need for Fed independence from political influence, a stance that may affect his confirmation prospects amid Trump's push for lower interest rates.
- Market Volatility: The Nasdaq Composite ended its longest winning streak since 1992, while the S&P 500 also retreated, as market uncertainty grew due to Trump's military threats against Iran; however, small-cap stocks showed resilience, with the Russell 2000 reaching new highs.
- UnitedHealth Group Strong Performance: UnitedHealth Group's first-quarter results exceeded expectations, leading to a more than 7% stock price increase, driven by improved management of medical costs and a favorable medical benefit ratio, with optimistic earnings outlook for 2026 further boosting investor confidence.
See More
Apple's CEO Transition Sparks Market Reactions
- CEO Transition Impact: Apple announced that hardware chief John Ternus will replace Tim Cook as CEO in September, with Cook moving to executive chairman; this shocking news is viewed positively as Ternus faces the challenge of bridging the AI gap with competitors.
- Fed Nomination Hearing: Kevin Warsh, Trump's nominee for Federal Reserve chair, will face the Senate Banking Committee for confirmation, emphasizing the need for Fed independence from political influence, a stance that may affect his confirmation process.
- Market Volatility: The Nasdaq Composite ended its longest winning streak since 1992, while the S&P 500 also retreated, as market uncertainty grew due to Trump's military threats against Iran, although small-cap stocks showed strong performance.
- UnitedHealth Group's Strong Performance: UnitedHealth Group's first-quarter results exceeded expectations, leading to a more than 7% stock price increase and an upgraded earnings outlook for 2026, driven by improved management of medical costs, which is crucial for its profitability.
See More
